StockNews.AI
AXSM
StockNews.AI
133 days

Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm

1. Kuehn Law is investigating Axsome's insider practices. 2. AXSM's CMC practices for AXS-07 allegedly deficient. 3. FDA approval for AXS-07 now uncertain due to unresolved issues. 4. Misrepresentation of AXS-07's regulatory and commercial prospects cited. 5. AXSM shareholders urged to participate in litigation for potential claims.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations of misrepresentation and the uncertainty around AXS-07's approval significantly harm investor confidence, akin to historical issues faced by biotech firms like Amarin during litigation-related downturns.

How important is it?

The investigation could lead to severe regulatory and perception issues, directly impacting AXSM's stock values and investor trust.

Why Short Term?

Ongoing litigation and pending FDA decisions can create immediate volatility, similar to instances witnessed in other pharmaceutical firms post-legal revelations.

Related Companies

AMRNPTCTXENE
, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Axsome caused the company to misrepresent or fail to disclose (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times. If you are a long-term AXSM stockholder please contact Justin Kuehn, Esq. here, by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  Why Your Participation Matters: As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™ For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts:Kuehn Law, PLLCJustin Kuehn, Esq.53 Hill Street, Suite 605Southampton, NY 11968[email protected](833) 672-0814 SOURCE Kuehn Law, PLLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News